(Q41962742)

14 October 2017

Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer (English)

1 reference

14 October 2017

6

David R Gandara

1 reference

14 October 2017

7

Alex A Adjei

1 reference

14 October 2017

Yingwei Qi

1

1 reference

14 October 2017

Katie L Allen Ziegler

2

1 reference

14 October 2017

Shauna L Hillman

3

1 reference

14 October 2017

Mary W Redman

4

1 reference

14 October 2017

Steven E Schild

5

1 reference

14 October 2017

Sumithra J Mandrekar

8

1 reference

14 October 2017

language of work or name

English

0 references

publication date

20 March 2012

1 reference

14 October 2017

1 reference

14 October 2017

118

1 reference

14 October 2017

21

1 reference

14 October 2017

5358-5365

1 reference

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Blinded independent central review of the progression-free survival endpoint

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Detecting an overall survival benefit that is derived from progression-free survival

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Endpoints in phase II trials for advanced non-small cell lung cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Proposal for the use of progression-free survival in unblinded randomized trials

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Generalized log-rank test for mixed interval-censored failure time data

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Analysis of tumor burden versus progression-free survival for Phase II decision making.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3481159

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

18 August 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27528

When you look matters: the effect of assessment schedule on progression-free survival

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22434489

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Progression-free survival remains debatable endpoint in cancer trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22434489

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CNCR.27528

1 reference

14 October 2017

1 reference

14 October 2017

PubMed publication ID

22434489

1 reference